Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Senaparib and Bevacizumab Maintenance in Newly Diagnosed Advanced HRP Ovarian Cancer
NCT07120451Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Oct 2025
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of senaparib in ovarian cancer, sponsored by Fudan University. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
senaparib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT07120451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07120451.